Cargando…
Efficacy and potential use of novel sustained release fillers as intracanal medicaments against Enterococcus faecalis biofilm in vitro
BACKGROUND: Enterococcus faecalis is a bacterium frequently isolated after failed root canal therapy. This study analyzed the antibacterial and antibiofilm effects in vitro of sustained-release fillers (SRF) containing cetylpyridinium chloride (CPC) against vancomycin resistant E. faecalis. METHODS:...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700812/ https://www.ncbi.nlm.nih.gov/pubmed/31429746 http://dx.doi.org/10.1186/s12903-019-0879-1 |
_version_ | 1783444936960507904 |
---|---|
author | Funk, Bernhard Kirmayer, David Sahar-Heft, Sharonit Gati, Irith Friedman, Michael Steinberg, Doron |
author_facet | Funk, Bernhard Kirmayer, David Sahar-Heft, Sharonit Gati, Irith Friedman, Michael Steinberg, Doron |
author_sort | Funk, Bernhard |
collection | PubMed |
description | BACKGROUND: Enterococcus faecalis is a bacterium frequently isolated after failed root canal therapy. This study analyzed the antibacterial and antibiofilm effects in vitro of sustained-release fillers (SRF) containing cetylpyridinium chloride (CPC) against vancomycin resistant E. faecalis. METHODS: First, the solidification capability was tested by introducing liquid SRF into phosphate buffered saline, followed by 30 s of vortexing. The antimicrobial effects of SRF-CPC against static monospecies biofilms were analyzed with a metabolic assay. Inhibition of biofilm formation was tested by exposing daily refreshed E. faecalis suspensions to SRF-CPC for 9 weeks. To evaluate the effects of SRF-CPC against preformed biofilms, biofilms were grown for 1, 3 and 7 days, and then treated with SRF-CPC for 24 h. Biofilm kill time was tested by applying SRF-CPC to a 3-day-old biofilm and measuring its viability at different time points. All experiments were compared to Placebo SRFs and to untreated control biofilms. Data were analyzed with two-way ANOVA followed by Tukey’s test. Results were considered significant at P < 0.05. RESULTS: The liquid SRF solidified within seconds and no structural changes were observed after 30 s of vortexing at maximum speed. SRF-CPC inhibited E. faecalis biofilm formation for 7 weeks and significantly reduced its viability in weeks 8 and 9. Mature biofilms grown for 1, 3 and 7 days were destructed by SRF-CPC in less than 24 h. Fifty percent of a 3-day-old biofilm was destructed in 2 h and complete destruction occurred in less than 12 h. (P < 0.05 in all cases, compared to SRII-Placebo). CONCLUSIONS: SRF-CPC’s physical properties and long-lasting anti-biofilm effects make it a promising coadjuvant medication for endodontic therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12903-019-0879-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6700812 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-67008122019-08-26 Efficacy and potential use of novel sustained release fillers as intracanal medicaments against Enterococcus faecalis biofilm in vitro Funk, Bernhard Kirmayer, David Sahar-Heft, Sharonit Gati, Irith Friedman, Michael Steinberg, Doron BMC Oral Health Research Article BACKGROUND: Enterococcus faecalis is a bacterium frequently isolated after failed root canal therapy. This study analyzed the antibacterial and antibiofilm effects in vitro of sustained-release fillers (SRF) containing cetylpyridinium chloride (CPC) against vancomycin resistant E. faecalis. METHODS: First, the solidification capability was tested by introducing liquid SRF into phosphate buffered saline, followed by 30 s of vortexing. The antimicrobial effects of SRF-CPC against static monospecies biofilms were analyzed with a metabolic assay. Inhibition of biofilm formation was tested by exposing daily refreshed E. faecalis suspensions to SRF-CPC for 9 weeks. To evaluate the effects of SRF-CPC against preformed biofilms, biofilms were grown for 1, 3 and 7 days, and then treated with SRF-CPC for 24 h. Biofilm kill time was tested by applying SRF-CPC to a 3-day-old biofilm and measuring its viability at different time points. All experiments were compared to Placebo SRFs and to untreated control biofilms. Data were analyzed with two-way ANOVA followed by Tukey’s test. Results were considered significant at P < 0.05. RESULTS: The liquid SRF solidified within seconds and no structural changes were observed after 30 s of vortexing at maximum speed. SRF-CPC inhibited E. faecalis biofilm formation for 7 weeks and significantly reduced its viability in weeks 8 and 9. Mature biofilms grown for 1, 3 and 7 days were destructed by SRF-CPC in less than 24 h. Fifty percent of a 3-day-old biofilm was destructed in 2 h and complete destruction occurred in less than 12 h. (P < 0.05 in all cases, compared to SRII-Placebo). CONCLUSIONS: SRF-CPC’s physical properties and long-lasting anti-biofilm effects make it a promising coadjuvant medication for endodontic therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12903-019-0879-1) contains supplementary material, which is available to authorized users. BioMed Central 2019-08-20 /pmc/articles/PMC6700812/ /pubmed/31429746 http://dx.doi.org/10.1186/s12903-019-0879-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Funk, Bernhard Kirmayer, David Sahar-Heft, Sharonit Gati, Irith Friedman, Michael Steinberg, Doron Efficacy and potential use of novel sustained release fillers as intracanal medicaments against Enterococcus faecalis biofilm in vitro |
title | Efficacy and potential use of novel sustained release fillers as intracanal medicaments against Enterococcus faecalis biofilm in vitro |
title_full | Efficacy and potential use of novel sustained release fillers as intracanal medicaments against Enterococcus faecalis biofilm in vitro |
title_fullStr | Efficacy and potential use of novel sustained release fillers as intracanal medicaments against Enterococcus faecalis biofilm in vitro |
title_full_unstemmed | Efficacy and potential use of novel sustained release fillers as intracanal medicaments against Enterococcus faecalis biofilm in vitro |
title_short | Efficacy and potential use of novel sustained release fillers as intracanal medicaments against Enterococcus faecalis biofilm in vitro |
title_sort | efficacy and potential use of novel sustained release fillers as intracanal medicaments against enterococcus faecalis biofilm in vitro |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700812/ https://www.ncbi.nlm.nih.gov/pubmed/31429746 http://dx.doi.org/10.1186/s12903-019-0879-1 |
work_keys_str_mv | AT funkbernhard efficacyandpotentialuseofnovelsustainedreleasefillersasintracanalmedicamentsagainstenterococcusfaecalisbiofilminvitro AT kirmayerdavid efficacyandpotentialuseofnovelsustainedreleasefillersasintracanalmedicamentsagainstenterococcusfaecalisbiofilminvitro AT saharheftsharonit efficacyandpotentialuseofnovelsustainedreleasefillersasintracanalmedicamentsagainstenterococcusfaecalisbiofilminvitro AT gatiirith efficacyandpotentialuseofnovelsustainedreleasefillersasintracanalmedicamentsagainstenterococcusfaecalisbiofilminvitro AT friedmanmichael efficacyandpotentialuseofnovelsustainedreleasefillersasintracanalmedicamentsagainstenterococcusfaecalisbiofilminvitro AT steinbergdoron efficacyandpotentialuseofnovelsustainedreleasefillersasintracanalmedicamentsagainstenterococcusfaecalisbiofilminvitro |